News

Reprogenetics will announce this to clients at the Florida Society of Reproductive Endocrinology and Infertility Meeting (FSREI), Saturday, August 16 at The Ritz-Carlton in Orlando. Rounding out its

To date, there have been no complaints or adverse events reported that can be attributed to the presence of these particles. Evaluations by Amgen found a very low

Under the deal, Allergan paid $67.5m in cash upfront, subject to certain adjustments and holdbacks, and has also agreed to pay up to an aggregate of $295m in

Lesinurad is an investigational agent that inhibits the URAT1 transporter, increasing uric acid excretion and thereby reduces serum uric acid (sUA). The CLEAR1 and CLEAR2 trials studied lesinurad

On the other side of the coin, research suggests that vitamin D could play a role in the prevention and treatment of diabetes, hypertension, glucose intolerance, multiple sclerosis,

The company said that the authorized generic version’s formulation is same as the original drug, Eloxatin, for which it holds the original patent. Eloxatin is a platinum-based drug,

The company, which is collaborating with Regeneron Pharmaceuticals on the global development of Eylea, intends for an immediate roll-out with Germany being one of the first launch countries

OS2966 is a first in class therapeutic being evaluated in multiple models of highly aggressive and resistant solid cancers. Glioblastoma is the most common and deadliest primary adult

As part of the deal, Liomont will seek regulatory approval for Flublok in Mexico and initially sell the product manufactured by Protein Sciences. Liomont has also secured rights